24 February 2022 
EMA/CHMP/72381/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Quviviq 
daridorexant 
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Quviviq, 
intended for the treatment of insomnia. The applicant for this medicinal product is Idorsia 
Pharmaceuticals Deutschland GmbH. 
Quviviq will be available as 25 mg and 50 mg film-coated tablets. The active substance of Quviviq is 
daridorexant which works as dual orexin receptor antagonist. 
The benefits of Quviviq are its ability to increase sleep induction, improve sleep maintenance and improve 
symptoms of daytime functioning. The most common side effects are headache and somnolence. 
The full indication is: 
Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present 
for at least 3 months and considerable impact on daytime functioning. 
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
